| 000 | 01806 a2200529 4500 | ||
|---|---|---|---|
| 005 | 20250518054100.0 | ||
| 264 | 0 | _c20200108 | |
| 008 | 202001s 0 0 eng d | ||
| 022 | _a1471-2407 | ||
| 024 | 7 |
_a10.1186/s12885-019-5971-z _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aGauthier, Martin | |
| 245 | 0 | 0 |
_aPrognostic role of CD4 T-cell depletion after frontline fludarabine, cyclophosphamide and rituximab in chronic lymphocytic leukaemia. _h[electronic resource] |
| 260 |
_bBMC cancer _cAug 2019 |
||
| 300 |
_a809 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xadverse effects |
| 650 | 0 | 4 |
_aCD4-Positive T-Lymphocytes _xdrug effects |
| 650 | 0 | 4 |
_aCyclophosphamide _xadverse effects |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunoglobulin Variable Region _xgenetics |
| 650 | 0 | 4 |
_aImmunosuppressive Agents _xadverse effects |
| 650 | 0 | 4 |
_aLeukemia, Lymphocytic, Chronic, B-Cell _xdiagnosis |
| 650 | 0 | 4 | _aLymphocyte Count |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aMutation |
| 650 | 0 | 4 | _aNeoplasm, Residual |
| 650 | 0 | 4 | _aPrognosis |
| 650 | 0 | 4 |
_aRituximab _xadverse effects |
| 650 | 0 | 4 | _aSurvival Analysis |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aVidarabine _xadverse effects |
| 700 | 1 | _aDurrieu, Françoise | |
| 700 | 1 | _aMartin, Elodie | |
| 700 | 1 | _aPeres, Michael | |
| 700 | 1 | _aVergez, François | |
| 700 | 1 | _aFilleron, Thomas | |
| 700 | 1 | _aObéric, Lucie | |
| 700 | 1 | _aBijou, Fontanet | |
| 700 | 1 | _aQuillet Mary, Anne | |
| 700 | 1 | _aYsebaert, Loic | |
| 773 | 0 |
_tBMC cancer _gvol. 19 _gno. 1 _gp. 809 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1186/s12885-019-5971-z _zAvailable from publisher's website |
| 999 |
_c30005676 _d30005676 |
||